<a href="https://laohu8.com/S/XAIR">Beyond Air</a> Inc. Reports 157% Increase in Revenues to $1.8 Million for Q1 2026; Net Loss Narrows to $7.7 Million, EPS Improves to ($1.53)
Beyond Air, Inc., a commercial stage medical device and biopharmaceutical company, reported a 157% increase in revenues to $1.8 million for the fiscal quarter ended June 30, 2025, compared to $0.7 million for the same period in 2024. The company also recognized a gross profit of $0.2 million for the quarter, an improvement from a gross loss of $0.3 million in the previous year. Despite these gains, Beyond Air reported a net loss of $7.7 million for the quarter, compared to a net loss of $12.2 million for the same quarter in 2024. The company has reaffirmed its revenue guidance of $12 to $16 million for the fiscal year ending March 31, 2026. Additionally, Beyond Air was awarded a national group purchasing agreement for therapeutic gases by Premier, Inc., which includes a network of over 4,350 member hospitals and health systems.
Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Beyond Air Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001641172-25-024647), on August 18, 2025, and is solely responsible for the information contained therein.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.